PCI looks to Boston for growth; 3M signs on to help Mylan make generic Advair;

> Contract drugmaker PCI Synthesis is increasingly looking to its native Boston for partnership deals, tapping the area's fast-growing biotech ecosystem to flesh out its client base. Story

> 3M ($MMM) has signed on to help Mylan ($MYL) manufacture the delivery device key to its generic version of GlaxoSmithKline's ($GSK) blockbuster COPD treatment Advair. News

Suggested Articles

Health organization NSF International is delving deeper into life sciences after buying up the majority stake of CRO Amarex Clinical Research.

As Covance changes up its leadership amid a change at the top of its parent company, one of its former execs has jumped ship to midsize rival CRO.

Contract research bigwig Parexel and Vivek Ramaswamy’s Datavant are deepening their trial tech partnership with a new, multiyear deal.